Статті в журналах з теми "Chemotherapy-induced febrile neutropenia; cancer patients; prognostic model"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 статей у журналах для дослідження на тему "Chemotherapy-induced febrile neutropenia; cancer patients; prognostic model".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
Chantharakhit, Chaichana, and Nantapa Sujaritvanichpong. "Pretreatment Absolute Neutrophil-to-Lymphocyte Ratio (NLR) Predict the Risk for Febrile Neutropenia in the First Cycle Adjuvant Chemotherapy for Breast Cancer." Asian Pacific Journal of Cancer Biology 5, no. 3 (September 15, 2020): 81–87. http://dx.doi.org/10.31557/apjcb.2020.5.3.81-87.
Повний текст джерелаCarmona-Bayonas, Alberto, Paula Jiménez-Fonseca, Juan Virizuela Echaburu, Maite Antonio, Carme Font, Mercè Biosca, Avinash Ramchandani, et al. "Prediction of Serious Complications in Patients With Seemingly Stable Febrile Neutropenia: Validation of the Clinical Index of Stable Febrile Neutropenia in a Prospective Cohort of Patients From the FINITE Study." Journal of Clinical Oncology 33, no. 5 (February 10, 2015): 465–71. http://dx.doi.org/10.1200/jco.2014.57.2347.
Повний текст джерелаShirakawa, Tsuyoshi, Ken Kato, Naoki Takahashi, Hirokazu Shoji, Tetsuji Terazawa, Yoshitaka Honma, Satoru Iwasa, et al. "A retrospective comparison study of docetaxel and paclitaxel for patients with advanced or recurrent esophageal cancer who previously received fluoropyrimidine and platinum-based chemotherapy." Journal of Clinical Oncology 31, no. 4_suppl (February 1, 2013): 112. http://dx.doi.org/10.1200/jco.2013.31.4_suppl.112.
Повний текст джерелаColombo Bonadio, Renata RC, Renata Gondim Meira Velame Azevedo, Guilherme Harada, Vanessa Costa Miranda, Patricia Alves de Oliveira Ferreira, Daniela Freitas, Elias Abdo Filho, Flavia Gabrielli, Maria Del Pilar Estevez-Diz, and Samantha Cabral Severino da Costa. "Adjuvant carboplatin and paclitaxel chemotherapy followed by radiotherapy in high-risk endometrial cancer: A retrospective analysis." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): e17115-e17115. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e17115.
Повний текст джерелаLee, Y. M. "Prognostic factors for adult cancer patients with chemotherapy-induced febrile neutropenia: a systematic review." International Journal of Evidence-Based Healthcare 10, no. 3 (September 2012): 273. http://dx.doi.org/10.1097/01258363-201209000-00108.
Повний текст джерелаGarcía de Guadiana-Romualdo, Luis, Ignacio Español-Morales, María Dolores Albaladejo-Otón, Ana Hernando-Holgado, Enrique Jiménez-Santos, Patricia Esteban-Torrella, and Pablo Cerezuela-Fuentes. "Prognostic value of procalcitonin and lipopolysaccharide binding protein in cancer patients with chemotherapy-associated febrile neutropenia presenting to an emergency department." Biochemia medica 29, no. 1 (December 24, 2018): 57–67. http://dx.doi.org/10.11613/bm.2019.010702.
Повний текст джерелаLee, Yee Mei, and Dora Lang. "Prognostic indicators predictive of chemotherapy-induced febrile neutropenia outcomes in adult cancer patients: a systematic review." JBI Database of Systematic Reviews and Implementation Reports 9, Supplement (2011): 1–18. http://dx.doi.org/10.11124/01938924-201109641-00025.
Повний текст джерелаLee, Yee Mei, and Dora Lang. "Prognostic indicators predictive of chemotherapy-induced febrile neutropenia outcomes in adult cancer patients: a systematic review." JBI Library of Systematic Reviews 9, Supplement (2011): 1–18. http://dx.doi.org/10.11124/jbisrir-2011-535.
Повний текст джерелаChao, Chun, John H. Page, Roberto Rodriguez, Su-Jau Yang, Julie Huynh, and Victoria M. Chia. "Chronic Comorbidities and Chemotherapy-Induced Febrile Neutropenia in Patients with Non-Hodgkin Lymphoma." Blood 120, no. 21 (November 16, 2012): 3671. http://dx.doi.org/10.1182/blood.v120.21.3671.3671.
Повний текст джерелаVoog, Eric, Jacques Bienvenu, Krzysztof Warzocha, Isabelle Moullet, Charles Dumontet, Catherine Thieblemont, Guillaume Monneret, Marie-Claude Gutowski, Bertrand Coiffier, and Gilles Salles. "Factors That Predict Chemotherapy-Induced Myelosuppression in Lymphoma Patients: Role of the Tumor Necrosis Factor Ligand-Receptor System." Journal of Clinical Oncology 18, no. 2 (January 1, 2000): 325. http://dx.doi.org/10.1200/jco.2000.18.2.325.
Повний текст джерелаYamanaka, T., S. Matsumoto, S. Teramukai, R. Ishiwata, Y. Nagai, and M. Fukushima. "Predictive value of chemotherapy-induced neutropenia for drug efficacy in advanced gastric carcinoma: Analysis of prospective nationwide survey." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 15075. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.15075.
Повний текст джерелаSaramago, P., V. Andreozzi, J. M. Ferreira, and J. Félix. "Modelling the direct costs of chemotherapy-induced neutropenia treatment in Portuguese hospitals clinical practice." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 17081. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.17081.
Повний текст джерелаGaur, Rachana, Rahul Bhardwaj, Sandeep Sharma, and Krishna Kumar Rathnam. "Clinical study of chemotherapy induced febrile neutropenia: talcott’s versus multinational association for supportive care in cancer risk assessment scoring systems." International Journal of Research in Medical Sciences 9, no. 1 (December 28, 2020): 236. http://dx.doi.org/10.18203/2320-6012.ijrms20205851.
Повний текст джерелаNijhuis, Claudi Oude, Willem A. Kamps, Simon M. G. Daenen, Jourik A. Gietema, Winette T. A. van der Graaf, Harrie J. M. Groen, Edo Vellenga, et al. "Feasibility of Withholding Antibiotics in Selected Febrile Neutropenic Cancer Patients." Journal of Clinical Oncology 23, no. 30 (October 20, 2005): 7437–44. http://dx.doi.org/10.1200/jco.2004.00.5264.
Повний текст джерелаHansen, Bent-Are, Øystein Wendelbo, Øyvind Bruserud, Anette Lodvir Hemsing, Knut Anders Mosevoll, and Håkon Reikvam. "FEBRILE NEUTROPENIA IN ACUTE LEUKEMIA. EPIDEMIOLOGY, ETIOLOGY, PATHOPHYSIOLOGY AND TREATMENT." Mediterranean Journal of Hematology and Infectious Diseases 12, no. 1 (December 30, 2019): e2020009. http://dx.doi.org/10.4084/mjhid.2020.009.
Повний текст джерелаDuh, M., E. L. Toy, C. L. Porter, P. L. Books, F. Vekeman, V. Barghout, and A. T. Skarin. "Budget impact analysis of sargramostim use in patients with chemotherapy-induced neutropenia." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): e20596-e20596. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e20596.
Повний текст джерелаLee, Yee Mei, Dora Lang, and Craig Lockwood. "Prognostic factors for risk stratification of adult cancer patients with chemotherapy-induced febrile neutropenia: a systematic review and meta-analysis." JBI Library of Systematic Reviews 10, no. 40 (2012): 2593–657. http://dx.doi.org/10.11124/jbisrir-2012-31.
Повний текст джерелаLee, Yee Mei, and Craig Lockwood. "Prognostic factors for risk stratification of adult cancer patients with chemotherapy-induced febrile neutropenia: A systematic review and meta-analysis." International Journal of Nursing Practice 19, no. 6 (June 14, 2013): 557–76. http://dx.doi.org/10.1111/ijn.12099.
Повний текст джерелаWong, M. D., D. Hershman, V. A. Morrison, B. Ding, and J. L. Malin. "Use of colony stimulating factors (CSF) for primary prophylaxis of chemotherapy-induced neutropenia in community oncology practices to reduce risk of febrile neutropenia (FN)." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 17013. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.17013.
Повний текст джерелаLi, Yanli, Leila Family, Lie Hong Chen, John H. Page, Zandra K. Klippel, Lanfang Xu, and Chun Chao. "Value of Incorporating Newly Identified Risk Factors into Risk Prediction for Chemotherapy-Induced Febrile Neutropenia (FN)." Blood 128, no. 22 (December 2, 2016): 4797. http://dx.doi.org/10.1182/blood.v128.22.4797.4797.
Повний текст джерелаErdem, Dilek, Idris Yucel, Bahiddin Yilmaz, Guzin Demirag, Yasemin Kemal, and Fatih Teker. "Baseline lymphopenia as a prognostic marker for colorectal carcinoma." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): e14107-e14107. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e14107.
Повний текст джерелаÁlvarez, José C., Sonia I. Cuervo, Edelberto Silva, Jorge A. Díaz, Lorena L. Jiménez, Daniel S. Parra, Julio C. Gómez, Ricardo Sánchez, and Jorge A. Cortés. "Pharmacokinetics and Pharmacodynamics of Cefepime in Adults with Hematological Malignancies and Febrile Neutropenia after Chemotherapy." Antibiotics 10, no. 5 (April 29, 2021): 504. http://dx.doi.org/10.3390/antibiotics10050504.
Повний текст джерелаWang, Weijia, Sanjeev Balu, and Kim Campbell. "Cost-minimization analysis for biosimilar pegfilgrastim in the prophylaxis of chemotherapy induced (febrile) neutropenia and expanded access based on budget neutral basis." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): 6645. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.6645.
Повний текст джерелаShirasaki, Ryosuke, Nobu Akiyama, Haruko Tashiro, Takuji Matsuo, Tadashi Yamamoto, Yoko Oka, Kazuo Kawasugi, and Naoki Shirafuji. "3D index calculated from duration and severity of neutropenia and a degree of fever as prognostic factors predicting mortality of chemotherapy-induced febrile neutropenia in hematologic malignancies." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 9053. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.9053.
Повний текст джерелаSanna, Marco, Giovanni Caocci, Antonio Ledda, Elisabetta Belardinelli, Pietro Garau, Alessandro Fanni, Claudio Romani, and Giorgio La Nasa. "Identification of a Predictive Pre-Chemotherapy Score for Febrile Neutropenia - the Fnipi INDEX." Blood 136, Supplement 1 (November 5, 2020): 16–17. http://dx.doi.org/10.1182/blood-2020-134659.
Повний текст джерелаJeurkar, Chetan, Tiffany Pompa, Ho-man Yeung, Pamela A. Crilley, David Lane Topolsky, and Michael Styler. "Chemotherapy-induced neutropenia risk models to guide the use of myeloid stimulating factors in intermediate risk chemotherapy: A cost and practicality analysis." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): 10086. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.10086.
Повний текст джерелаKan, Motoyasu, Hiroshi Imaoka, Masafumi Ikeda, Shuichi Mitsunaga, Izumi Ohno, Yusuke Hashimoto, Mitsuhito Sasaki, et al. "Chemotherapy-induced neutropenia as a prognostic factor in patients with unresectable pancreatic cancer treated with gemcitabine and nab-paclitaxel." Journal of Clinical Oncology 37, no. 4_suppl (February 1, 2019): 324. http://dx.doi.org/10.1200/jco.2019.37.4_suppl.324.
Повний текст джерелаNina, Lathi A., Pierre Isogai, Nicole Mittmann, Carlo DeAngelis, Matthew Cheung, Knowles Sandra, Eugenia Piliotis, Neil Shear, and Scott Walker. "Comprehensiveness of Quality of Life Instruments in Capturing Concerns Related to Chemotherapy-Induced Neutropenia." Blood 112, no. 11 (November 16, 2008): 1311. http://dx.doi.org/10.1182/blood.v112.11.1311.1311.
Повний текст джерелаLim, Joo Han, Hyeon Gyu Yi, Moon Hee Lee, Hoon Kim, and Chul Soo Kim. "Chemotherapy Induced Neutropenic Fever Seen at Emergency Room: A Review of 102 Cases." Blood 114, no. 22 (November 20, 2009): 4530. http://dx.doi.org/10.1182/blood.v114.22.4530.4530.
Повний текст джерелаCasas, A. M., J. Rifà, J. L. González Larriba, A. Carrato, and A. López Pousa. "Risk assessment model for haematologic toxicity (HT) in patients with solid tumours (ST) during the first chemotherapy (CT) cycle." Journal of Clinical Oncology 24, no. 18_suppl (June 20, 2006): 18516. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.18516.
Повний текст джерелаWang, Weijia, Edward Li, Kim Campbell, Ali McBride, and Steve D'Amato. "Economic Analysis on Adoption of Biosimilar Granulocyte Colony-Stimulating Factors in Patients With Nonmyeloid Cancer at Risk of Febrile Neutropenia Within the Oncology Care Model Framework." JCO Oncology Practice 17, no. 8 (August 2021): e1139-e1149. http://dx.doi.org/10.1200/op.20.00994.
Повний текст джерелаHershenfeld, Samantha A., Kimberly Maki, Lana Rothfels, Cindy Susan Murray, Aaron D. Schimmer, and Mary Doherty. "Sharing Post-AML Consolidation Supportive Therapy with Local Centers Reduces Patient Travel Burden without Compromising Safety and Efficacy of Care." Blood 126, no. 23 (December 3, 2015): 534. http://dx.doi.org/10.1182/blood.v126.23.534.534.
Повний текст джерелаBanh, Cindy, Kendall Valsvik, Alejandra Arredondo, Kassie Notbohm, Abhijeet Kumar, Lee D. Cranmer, Andrew S. Kraft, Ivo Abraham, and Ali McBride. "Transitioning adriamycin ifosfamide mesna (AIM) chemotherapy in sarcoma patients to the outpatient setting: Evaluation of outpatient chemotherapy in an oncology care model setting." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): e19149-e19149. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e19149.
Повний текст джерелаBozec, Alexandre, Nicolas Fakhry, Charlotte Dupuis, Benjamin Lallemant, Marc Alfonsi, Karen Benezery, Christian Righini, et al. "Induction chemotherapy with docetaxel, cisplatin, and 5FU (TPF) in unresectable advanced head and neck squamous cell carcinoma: Retrospective analysis of 300 cases and proposal for a prognostic index." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): e16055-e16055. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e16055.
Повний текст джерелаLi, Edward C., Dylan Mezzio, Kimberley J. Campbell, Andrew Spargo, and Gary H. Lyman. "Cost-effectiveness of filgrastim-sndz as primary prophylaxis (PP) versus secondary prophylaxis (SP) to prevent chemotherapy-induced febrile neutropenia (FN) in breast cancer patients at intermediate risk." Journal of Clinical Oncology 38, no. 29_suppl (October 10, 2020): 73. http://dx.doi.org/10.1200/jco.2020.38.29_suppl.73.
Повний текст джерелаO'Halloran, Katrina, Sheetal Phadnis, Laura Metrock, Gregory Friedman, Tom Davidson, Nathan Robison, Girish Dhall, and Ashley Margol. "MEDB-86. A re-induction regimen for children with recurrent medulloblastoma." Neuro-Oncology 24, Supplement_1 (June 1, 2022): i126—i127. http://dx.doi.org/10.1093/neuonc/noac079.460.
Повний текст джерелаLi, Edward C., Dylan Mezzio, Andrew Spargo, Kimberley J. Campbell, and Gary H. Lyman. "Cost-effectiveness of filgrastim-sndz as primary prophylaxis (PP) versus secondary prophylaxis (SP) to prevent chemotherapy-induced febrile neutropenia (FN) in non-small cell lung cancer (NSCLC) patients at intermediate risk." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): e19401-e19401. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e19401.
Повний текст джерелаMahipal, Amit, Gregory M. Springett, Nancy Burke, Barbara Bertels, Georgine Wapinsky, Khaldoun Almhanna, and Richard D. Kim. "Phase I trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer." Journal of Clinical Oncology 33, no. 3_suppl (January 20, 2015): 467. http://dx.doi.org/10.1200/jco.2015.33.3_suppl.467.
Повний текст джерелаLyman, Gary H., Dylan Mezzio, Edward C. Li, Kim Campbell, and Sanjeev Balu. "A cost-effectiveness analysis of primary prophylaxis (PP) versus secondary prophylaxis (SP) with biosimilar myeloid growth factors (MGFs) for preventing chemotherapy-induced febrile neutropenia (FN) in non-Hodgkin lymphoma (NHL) patients at intermediate risk." Journal of Clinical Oncology 37, no. 27_suppl (September 20, 2019): 107. http://dx.doi.org/10.1200/jco.2019.37.27_suppl.107.
Повний текст джерелаJimenez Gordo, Ana M., Gonzalo Colmenarejo, Javier Baena Espinar, Carlos Aguado, Xabier Mielgo, Ana Pertejo, Rosa Maria Alvarez Alvarez, et al. "A multicenter analysis of the outcome of cancer patients with neutropenia and COVID-19 infection optionally treated with granulocyte colony-stimulating factor (G-CSF)." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): 12105. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.12105.
Повний текст джерелаMcBride, Ali, Karen MacDonald, and Ivo Abraham. "Simulation modeling of budget-neutral expanded access to antineoplastic therapy from cost-savings derived from conversion to biosimilar pegfilgrastim-cbqv for the prophylaxis of chemotherapy-induced (febrile) neutropenia (CIN/FN) in early-stage breast cancer." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): e19371-e19371. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e19371.
Повний текст джерелаAntonuzzo, Andrea, Enrico Vasile, Maurizio Lucchesi, Laura Ginocchi, Luca Galli, Isa Maura Brunetti, Sergio Ricci, and Alfredo Falcone. "A new model of early supportive care and symptoms management: The experience of Pisa medical oncology." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): e20711-e20711. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e20711.
Повний текст джерелаMcBride, Ali, Karen MacDonald, and Ivo Abraham. "Cost efficiency and budget-neutral expanded access to antineoplastic therapy from cost-savings derived from conversion to biosimilar pegfilgrastim-cbqv for the prophylaxis of chemotherapy-induced (febrile) neutropenia (CIN/FN):Simulation modeling in metastatic pancreatic cancer." Journal of Clinical Oncology 39, no. 3_suppl (January 20, 2021): 441. http://dx.doi.org/10.1200/jco.2021.39.3_suppl.441.
Повний текст джерелаChien, Amy Jo, Amelia S. Gliwa, Siti Rahmaputri, Heidi F. Dittrich, Melanie Catherine Majure, Hope S. Rugo, Michelle E. Melisko, et al. "A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC) and response correlation with MYC-overexpression." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): 1076. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.1076.
Повний текст джерелаChien, Amy Jo, Siti Rahmaputri, Heidi F. Dittrich, Melanie Catherine Majure, Hope S. Rugo, Michelle E. Melisko, and Andrei Goga. "A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC)." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): 1072. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.1072.
Повний текст джерелаBlackwell, Kimberly, Vladimir Semiglazov, Pedro Gascon, Roumen Nakov, Stefan Kramer, Arnd Schwebig, and Nadia Harbeck. "A Comparison of Proposed Biosimilar and Originator Filgrastim for the Prevention of Neutropenia in Patients with Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Phase III, Randomized, Double-Blind Trial (The PIONEER study)." Blood 124, no. 21 (December 6, 2014): 5133. http://dx.doi.org/10.1182/blood.v124.21.5133.5133.
Повний текст джерелаSchlenk, Richard F., Jürgen Krauter, Markus Schaich, Didier Bouscary, Hervé Dombret, Ivo J. Winiger, Margaret Squier, Anita Zahlten, Lu Wang, and Oliver G. Ottmann. "Determination of the Maximum Tolerated Dose of Panobinostat in Combination with Cytarabine and Mitoxantrone As Salvage Therapy for Relapsed/Refractory Acute Myeloid Leukemia." Blood 118, no. 21 (November 18, 2011): 423. http://dx.doi.org/10.1182/blood.v118.21.423.423.
Повний текст джерелаMcBride, Ali, Karen MacDonald, and Ivo Abraham. "Simulation Modeling of Cost-Savings from Conversion to Biosimilar Pegfilgrastim-Cbqv for the Prophylaxis of Chemotherapy-Induced Neutropenia, and Budget-Neutral Expanded Access to Prophylaxis and Anti-Neoplastic Therapy from Derived Cost-Savings in Non-Hodgkin Lymphoma." Blood 136, Supplement 1 (November 5, 2020): 24–25. http://dx.doi.org/10.1182/blood-2020-136810.
Повний текст джерелаBixby, Dale, Matthew J. Wieduwilt, Luke Paul Akard, H. Jean Khoury, Pamela S. Becker, Edward H. Van Der Horst, William Ho, and Jorge E. Cortes. "A Phase I Study of IGN523, a Novel Anti-CD98 Monoclonal Antibody in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)." Blood 126, no. 23 (December 3, 2015): 3809. http://dx.doi.org/10.1182/blood.v126.23.3809.3809.
Повний текст джерелаWildiers, Hans, Sandrine Marreaud, Lissandra Dal Lago, Peter Vuylsteke, Giuseppe Curigliano, Simon Waters, Barbara Brouwers, et al. "Abstract P1-18-06: Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2- positive metastatic breast cancer, followed by T-DM1 after progression." Cancer Research 82, no. 4_Supplement (February 15, 2022): P1–18–06—P1–18–06. http://dx.doi.org/10.1158/1538-7445.sabcs21-p1-18-06.
Повний текст джерела